Mesalazine Mayoly (Mesalazine)

Mesalazine works by blocking the cyclooxygenase and lipoxygenase enzymes in the gut lining, which lowers the production of prostaglandins and leukotrienes—key mediators of inflammation. This reduction dampens immune cell activation, decreases cytokine release, and promotes healing of the colonic mucosa.

The exact dose of Mesalazine Mayoly is determined by the prescribing healthcare professional based on the individual’s disease severity, location, previous response to therapy, and any renal or hepatic impairment. Dosage adjustments are made according to clinical response and laboratory monitoring, not by a fixed over‑the‑counter regimen.

Safety data for mesalazine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and alternatives with their physician.

To request Mesalazine Mayoly, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Mesalazine belongs to the aminosalicylate class, which acts locally in the colon, whereas biologics such as anti‑TNF agents work systemically to suppress immune pathways. Compared with corticosteroids, mesalazine has a more favorable safety profile for long‑term maintenance but may be less potent for rapid induction of remission in severe disease.

Mesalazine Mayoly should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Mesalazine Mayoly is taken orally, usually as a tablet, with or without food as directed by the prescriber. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule provided by their healthcare professional and not split or crush tablets unless instructed.

Serious risks include severe hypersensitivity reactions such as rash, fever, or anaphylaxis, blood disorders like neutropenia or agranulocytosis, and kidney problems such as interstitial nephritis. Any signs of these conditions require immediate medical attention and discontinuation of the drug.

Patients with a known hypersensitivity to mesalazine, other aminosalicylates, or salicylate‑containing drugs should avoid this medication. It is also contraindicated in individuals with severe renal impairment where the drug cannot be safely cleared, and in those who have experienced previous severe adverse reactions to the product.